Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

Open access
Avvisati, Giuseppe, Lo-Coco, Francesco, Paoloni, Francesca Paola, Petti, Maria Concetta, Diverio, Daniela, Vignetti, Marco, Latagliata, Roberto, Specchia, Giorgina, Baccarani, Michele, Di Bona, Eros, Fioritoni, Giuseppe, Marmont, Filippo, Rambaldi, Alessandro, Di Raimondo, Francesco, Kropp, Maria Grazia, Pizzolo, Giovanni, Pogliani, Enrico M., Rossi, Giuseppe, Cantore, Nicola, Nobile, Francesco, Gabbas, Attilio, Ferrara, Felicetto, Fazi, Paola, Amadori, Sergio, Mandelli, Franco, for the GIMEMA, AIEOP, and EORTC Cooperative Groups · 2011 · Blood

Abstract

All-trans-retinoic acid (ATRA) has greatly modified the prognosis of acute promyelocytic leukemia; however, the role of maintenance in patients in molecular complete remission after consolidation treatment is still debated. From July 1993 to May 2000, 807 genetically proven newly diagnosed acute promyelocytic leukemia patients received ATRA plus idarubicin as induction, followed by 3 intensive consolidation courses. Thereafter, patients reverse-transcribed polymerase chain reaction–negative for the PML-RARA fusion gene were randomized into 4 arms: oral 6-mercaptopurine and intramuscular methotrexate (arm 1); ATRA alone (arm 2); 3 months of arm1 alternating to 15 days of arm 2 (arm 3); and no further therapy (arm 4). Starting from February 1997, randomization was limited to ATRA-containing arms only (arms 2 and 3). Complete remission was achieved in 761 of 807 (94.3%) patients, and 681 completed the consolidation program. Of these, 664 (97.5%) were evaluated for the PML-RARA fusion gene, and 586 of 646 (90.7%) who tested reverse-transcribed polymerase chain reaction–negative were randomized to maintenance. The event-free survival estimate at 12 years was 68.9% (95% confidence interval, 66.4%-71.4%), and no differences in disease-free survival at 12 years were observed among the maintenance arms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-08-302950

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 185

Metadata

Authors
Avvisati, G., Lo-Coco, F., Paoloni, F. P., Petti, M. C., Diverio, D., Vignetti, M., Latagliata, R., Specchia, G., Baccarani, M., Di Bona, E., Fioritoni, G., Marmont, F., Rambaldi, A., Di Raimondo, F., Kropp, M. G., Pizzolo, G., Pogliani, E. M., Rossi, G., Cantore, N., Nobile, F., Gabbas, A., Ferrara, F., Fazi, P., Amadori, S., Mandelli, F., & for the GIMEMA, A.
Venue
Blood
Published
2011-05-05
Volume
117
Issue
18
Pages
4716-4725
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2075957152
Cited by
185
References
1
FWCI
8.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. https://app.cochat.ai/papers/10.1182/blood-2010-08-302950
The paper
Avvisati, G., Lo-Coco, F., Paoloni, F. P., Petti, M. C., Diverio, D., Vignetti, M., Latagliata, R., Specchia, G., Baccarani, M., Di Bona, E., Fioritoni, G., Marmont, F., Rambaldi, A., Di Raimondo, F., Kropp, M. G., Pizzolo, G., Pogliani, E. M., Rossi, G., Cantore, N., . . . for the GIMEMA, A. (2011). AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. https://doi.org/10.1182/blood-2010-08-302950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.